デフォルト表紙
市場調査レポート
商品コード
1004400

院内感染症(HAI)治療薬市場:医薬品クラス(抗菌薬・抗ウイルス薬・抗真菌薬)・感染症タイプ・地域別 - 市場シェア・市場規模・動向・業界分析・予測(2021年~2028年)

Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 - 2028

出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
院内感染症(HAI)治療薬市場:医薬品クラス(抗菌薬・抗ウイルス薬・抗真菌薬)・感染症タイプ・地域別 - 市場シェア・市場規模・動向・業界分析・予測(2021年~2028年)
出版日: 2021年04月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の院内感染症(HAI)治療薬の市場規模は、2028年までに125億2,000万米ドルに達すると予測されています。

抗生物質に耐性をもつ致死性の病原体の増加によって、院内感染(HAI)治療の新薬の需要が促進されています。院内感染症(HAI)治療薬市場に参入する多くの企業は、競合における優位性を得るために、新薬開発を目的とした研究開発活動を継続的に行っています。

当レポートでは、世界の院内感染症(HAI)治療薬市場について調査し、市場の概要、セグメント・地域別の市場規模の推移と予測、市場の推進要因・抑制要因の分析、市場機会、課題、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • レポート概要
    • 調査目的
    • 市場規模
    • 仮定
  • ステークホルダー

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • データソース
    • 一次情報源
    • 二次情報源

第4章 市場洞察

  • 業界スナップショット
  • 市場力学
    • 推進要因と機会
    • 抑制要因と課題
  • ファイブフォース分析
    • 供給企業の交渉力(中)
    • 新規参入者の脅威(低)
    • 買い手の交渉力(中)
    • 代替品の脅威(中)
    • 競争企業間の敵対関係(高)
  • PESTLE分析
  • 業界動向

第5章 院内感染症(HAI)治療薬市場:医薬品クラス別

  • 主な調査結果
  • イントロダクション
    • 市場規模:医薬品クラス別(実績値・予測値)
  • 抗菌薬
    • 細胞壁合成阻害薬
    • タンパク質合成阻害薬
  • 抗ウイルス薬
  • 抗真菌薬

第6章 院内感染症(HAI)治療薬市場:感染症タイプ別

  • 主な調査結果
  • イントロダクション
    • 市場規模:感染症タイプ別(実績値・予測値)
  • 尿路感染症
  • 人工呼吸器感染症
  • 手術部位感染症
  • 血液感染症
  • その他

第7章 院内感染症(HAI)治療薬市場:地域別

  • 主な調査結果
  • イントロダクション
  • 北米
    • 市場規模:セグメント別(実績値・予測値)
    • 米国
    • カナダ
  • 欧州
    • 市場規模:セグメント別(実績値・予測値)
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • オーストリア
  • アジア太平洋地域
    • 市場規模:セグメント別(実績値・予測値)
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • 市場規模:セグメント別(実績値・予測値)
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ
    • イスラエル
  • ラテンアメリカ
    • 市場規模:セグメント別(実績値・予測値)
    • メキシコ
    • ブラジル
    • アルゼンチン

第8章 競合情勢

  • 拡大・買収
  • パートナーシップ・コラボレーション・契約・展示会

第9章 企業プロファイル

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo Company, Limited
  • AbbVie Inc.
  • Abbott Laboratories
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd
  • Basilea Pharmaceutica AG
図表

List of Tables

  • Table 1 Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 2 Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 3 Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)
  • Table 4 North America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 5 North America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 6 U.S.: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 7 U.S.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 8 Canada: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 9 Canada: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 10 Europe: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 11 Europe: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 12 UK: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 13 UK: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 14 France: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 15 France: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 16 Germany: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 17 Germany: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 18 Italy: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 19 Italy: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 20 Spain: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 21 Spain: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 22 Netherlands: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 23 Netherlands: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 24 Austria: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 25 Austria: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 26 Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 27 Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 28 China: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 29 China: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 30 India: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 31 India: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 32 Malaysia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 33 Malaysia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 34 Japan: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 35 Japan: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 36 Indonesia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 37 Indonesia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 38 South Korea: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 39 South Korea: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 40 Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 41 Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 42 Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 43 Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 44 UAE: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 45 UAE: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 46 Israel: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 47 Israel: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 48 South Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 49 South Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 50 Latin America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 51 Latin America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 52 Mexico: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 53 Mexico: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 54 Brazil: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 55 Brazil: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 56 Argentina: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 57 Argentina: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)

List of Figures

Figure 1 Market Highlights (2020, Revenue)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top Down & Bottom Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Drug Class

Figure 7 Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2020 & 2028 (USD Million)

Figure 8 Market by Infection Type

Figure 9 Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2020 & 2028 (USD Million)

Figure 10 Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)

Figure 11 Strategic Analysis - Hospital Acquired Infections Therapeutic Market

目次
Product Code: PM1866

The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research. The report "Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 - 2028" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections. The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.

In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck's Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older. This is expected to drive the market for hospital acquired infections therapeutic.

Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed. As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.

This has resulted in a rise in healthcare admissions and an increased possibility of getting an hospital acquired infection. Moreover, as per the data of the New York State Department of Health in November 2019, more than 40% of the adults in the state suffer from some form of chronic disorder, accounting for around 23% of all the hospitalizations.

Asia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period. This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.

For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China. Thus, with increased hospital admissions, the market demand for hospital acquired infections therapeutics is bound to rise. Market participants such as Merck, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited and Allergan Plc.

Polaris Market Research has segmented the hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

Hospital Acquired Infections Therapeutic, Drug Class Outlook (Revenue - USD Million, 2016 - 2028)

Antibacterial Drugs

Cell Wall Synthesis Inhibitors

Protein Synthesis Inhibitors

Others

Antiviral Drugs

Antifungal Drugs

Hospital Acquired Infections Therapeutic, Infection Type Outlook (Revenue - USD Million, 2016 - 2028)

Urinary Tract Infections

Ventilator-associated Pneumonia

Surgical Site Infections

Bloodstream Infections

Other Hospital Infections

Hospital Acquired Infections Therapeutic, by Regional Outlook (Revenue - USD Million, 2016 - 2028)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Central & South America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Hospital Acquired Infections Therapeutic Market Insights

  • 4.1. Hospital Acquired Infections Therapeutic - Industry snapshot
  • 4.2. Hospital Acquired Infections Therapeutic Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High prevalence of hospital acquired infections
      • 4.2.1.2. Cocerned research and innovation
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Antimicrobial resistance
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Hospital Acquired Infections Therapeutic Market Industry trends

5. Hospital Acquired Infections Therapeutic Market Assessment by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • 5.3. Antibacterial Drugs
    • 5.3.1. Global Hospital Acquired Infections Therapeutic Market, by Antibacterial Drugs, by Region, 2016 - 2028 (USD Million)
    • 5.3.2. Cell Wall Synthesis Inhibitors
      • 5.3.2.1. Cell Wall Synthesis Inhibitors Market, by Region, 2016 - 2028 (USD Million)
    • 5.3.3. Protein Synthesis Inhibitors
      • 5.3.3.1. Protein Synthesis Inhibitors Market, by Region, 2016 - 2028 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others Market, by Region, 2016 - 2028 (USD Million)
  • 5.4. Antiviral Drugs
    • 5.4.1. Global Hospital Acquired Infections Therapeutic Market, by Antiviral Drugs, by Region, 2016 - 2028 (USD Million)
  • 5.5. Antifungal Drugs
    • 5.5.1. Global Hospital Acquired Infections Therapeutic Market, by Antifungal Drugs, by Region, 2016 - 2028 (USD Million)

6. Global Hospital Acquired Infections Therapeutic Market, by Infection Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 6.3. Urinary Tract Infections
    • 6.3.1. Global Hospital Acquired Infections Therapeutic Market, by Urinary Tract Infections, By Region, 2016 - 2028 (USD Million)
  • 6.4. Ventilator-associated Pneumonia
    • 6.4.1. Global Hospital Acquired Infections Therapeutic Market, by Ventilator-associated Pneumonia, by Region, 2016 - 2028 (USD Million)
  • 6.5. Surgical Site Infections
    • 6.5.1. Global Hospital Acquired Infections Therapeutic Market, by Surgical Site Infections, by Region, 2016 - 2028 (USD Million)
  • 6.6. Bloodstream Infections
    • 6.6.1. Global Hospital Acquired Infections Therapeutic Market, by Bloodstream Infections, by Region, 2016 - 2028 (USD Million)
  • 6.7. Other Hospital Infections
    • 6.7.1. Global Hospital Acquired Infections Therapeutic Market, by Other Hospital Infections, by Region, 2016 - 2028 (USD Million)

7. Hospital Acquired Infections Therapeutic Market Assessment by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)
  • 7.3. Hospital Acquired Infections Therapeutic Market - North America
    • 7.3.1. North America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.3.2. North America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.3.3. Hospital Acquired Infections Therapeutic Market - U.S.
      • 7.3.3.1. U.S.: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.3.3.2. U.S.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.3.4. Hospital Acquired Infections Therapeutic Market - Canada
      • 7.3.4.1. Canada: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.3.4.2. Canada.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.4. Hospital Acquired Infections Therapeutic Market - Europe
    • 7.4.1. Europe: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.4.2. Europe: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.3. Hospital Acquired Infections Therapeutic Market - UK
      • 7.4.3.1. UK: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.3.2. UK: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.4. Hospital Acquired Infections Therapeutic Market - France
      • 7.4.4.1. France: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.4.2. France: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.5. Hospital Acquired Infections Therapeutic Market - Germany
      • 7.4.5.1. Germany: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.5.2. Germany: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.6. Hospital Acquired Infections Therapeutic Market - Italy
      • 7.4.6.1. Italy: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.6.2. Italy: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.7. Hospital Acquired Infections Therapeutic Market - Spain
      • 7.4.7.1. Spain: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.7.2. Spain: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.8. Hospital Acquired Infections Therapeutic Market - Netherlands
      • 7.4.8.1. Netherlands: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.8.2. Netherlands: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.9. Hospital Acquired Infections Therapeutic Market - Austria
      • 7.4.9.1. Austria: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.9.2. Austria: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.5. Hospital Acquired Infections Therapeutic Market - Asia-Pacific
    • 7.5.1. Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.5.2. Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.3. Hospital Acquired Infections Therapeutic Market - China
      • 7.5.3.1. China: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.3.2. China: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.4. Hospital Acquired Infections Therapeutic Market - India
      • 7.5.4.1. India: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.4.2. India.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.5. Hospital Acquired Infections Therapeutic Market - Malaysia
      • 7.5.5.1. Malaysia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.5.2. Malaysia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.6. Hospital Acquired Infections Therapeutic Market - Japan
      • 7.5.6.1. Japan: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.6.2. Japan: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.7. Hospital Acquired Infections Therapeutic Market - Indonesia
      • 7.5.7.1. Indonesia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.7.2. Indonesia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.8. Hospital Acquired Infections Therapeutic Market - South Korea
      • 7.5.8.1. South Korea: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.8.2. South Korea.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.6. Hospital Acquired Infections Therapeutic Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.6.2. Middle East & Africa.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.3. Hospital Acquired Infections Therapeutic Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.3.2. Saudi Arabia.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.4. Hospital Acquired Infections Therapeutic Market - UAE
      • 7.6.4.1. UAE: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.4.2. UAE: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.5. Hospital Acquired Infections Therapeutic Market - Israel
      • 7.6.5.1. Israel: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.5.2. Israel: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.6. Hospital Acquired Infections Therapeutic Market - South Africa
      • 7.6.6.1. South Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.6.2. South Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.7. Hospital Acquired Infections Therapeutic Market - Latin America
    • 7.7.1. Latin America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.7.2. Latin America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.3. Hospital Acquired Infections Therapeutic Market - Mexico
      • 7.7.3.1. Mexico: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.3.2. Mexico.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.4. Hospital Acquired Infections Therapeutic Market - Brazil
      • 7.7.4.1. Brazil: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.4.2. Brazil.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.5. Hospital Acquired Infections Therapeutic Market - Argentina
      • 7.7.5.1. Argentina: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.5.2. Argentina.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisition
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Merck & Co., Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Prooduct Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Pfizer Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Prooduct Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bayer AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Prooduct Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline Plc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Prooduct Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Daiichi Sankyo Company, Limited
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Prooduct Benchmarking
    • 9.5.4. Recent Development
  • 9.6. AbbVie Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Prooduct Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Abbott Laboratories
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Prooduct Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Allergan Plc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Prooduct Benchmarking
    • 9.8.4. Recent Development
  • 9.9. F. Hoffmann-La Roche Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Prooduct Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Basilea Pharmaceutica AG
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Prooduct Benchmarking
    • 9.10.4. Recent Development